Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation

Glycyrrhetinic acid induces G1-phase cell cycle arrest in human non-small cell lung cancer cells through endoplasmic reticulum stress pathway

(2015) JIE ZHU et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

(2015) David E. Gerber et al.   LUNG CANCER

Acetylproteomic Analysis Reveals Functional Implications of Lysine Acetylation in Human Spermatozoa (sperm)

(2015) Heguo Yu et al.   MOLECULAR & CELLULAR PROTEOMICS

Post-translational modifications of tubulin: pathways to functional diversity of microtubules

(2015) Yuyu Song et al.   TRENDS IN CELL BIOLOGY

Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line

(2015) Quan Wu et al.   Scientific Reports

Histone deacetylase inhibitors and cell death

(2014) Jing Zhang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

SAHA Treatment Reveals the Link between Histone Lysine Acetylation and Proteome in Nonsmall Cell Lung Cancer A549 Cells

(2013) Quan Wu et al.   JOURNAL OF PROTEOME RESEARCH

Histone acetylation: molecular mnemonics on the chromatin

(2013) Johannes Gräff et al.   NATURE REVIEWS NEUROSCIENCE

Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor

(2013) Eamon M. Berge et al.   SEMINARS IN ONCOLOGY

The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial–mesenchymal transition of lens epithelial cells

(2013) X Chen et al.   Cell Death & Disease

Lung cancer: potential targets for immunotherapy

(2013) Eric Tartour et al.   Lancet Respiratory Medicine

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

(2011) Claudia P. Miller et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors

(2010) Cliona Grant et al.   Expert Review of Anticancer Therapy

Histone deacetylase inhibition suppresses the transforming growth factor β1-induced epithelial-to-mesenchymal transition in hepatocytes

(2010) Aki Kaimori et al.   HEPATOLOGY

Induction of E-Cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition

(2010) Masatoshi Kakihana et al.   Journal of Thoracic Oncology

BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium-hydrogen exchanger: the alteration of mitochondrial function

(2010) G-H Lee et al.   ONCOGENE

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

(2009) J. Arts et al.   CLINICAL CANCER RESEARCH

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways

(2008) T. T. Onder et al.   CANCER RESEARCH

Acetylation Is Indispensable for p53 Activation

(2008) Yi Tang et al.   CELL